NeoBiocon partners Novartis to launch diabetes drugs in UAE

NeoBiocon, a collaboration between Biocon Ltd and BR Shetty led UAE-based Neopharma, has partnered with Novartis Middle East FZE to market diabetes drugs Jalra and Jalra-M in the UAE.

Novartis gets USFDA warning letter for two plants in India

Sandoz, the generic drug arm of Swiss drug major Novartis, has received a warning letter from the US health regulator for violations of current good manufacturing practice (cGMP) norms at its two plants in Western India.

GSK Pharma completes deal with Novartis Healthcare

GSK Pharma completes deal with Novartis Healthcare

The company has completed its transaction with Novartis Healthcare Pvt Ltd Wednesday whereby it has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis India, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.

Novartis flags margin increase, higher dividends, bolt-on deals

Novartis flags margin increase, higher dividends, bolt-on deals

Novartis AG said on Thursday it expects to increase its profit margin this year as it restructures its drug portfolio and cuts costs, as well as generate cash for a higher dividend and smaller, strategic acquisitions.

Ready to pay "reasonable" royalty to Novartis AG: Cipla to HC

Indian pharma firm Cipla Monday suggested to the Delhi High Court that it was ready to pay "reasonable" royalty to Switzerland-based drug major Novartis AG if it is allowed to manufacture respiratory disease drug, 'Indaflo', which could serve 66,000 patients in India at a cheaper rate.

Novartis okays OTC unit sale to GSK Consumer for Rs 109.7-cr

Novartis India's board on Tuesday approved the sale of its OTC division to GlaxoSmithKline Consumer Pvt Ltd, a consumer healthcare joint venture between Novartis AG and GSK, for a consideration of Rs 109.7 crore.

Novartis sues India's Cipla over respiratory drug Onbrez

Swiss drugmaker Novartis AG said on Wednesday it had sued India`s Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug`s price.

World's top drugmaker Novartis takes aim at tech

Talent spotters from Novartis AG, charged with bringing new ideas into the organisation, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology.

Eighth Princeton student diagnosed with meningitis

An eighth Princeton University student has been diagnosed with meningitis, a potentially fatal infection that causes swelling of the brain and spinal cord, a university spokesman said on Friday.

Novartis AG sells 1.42 stake in Indian arm for Rs 25 cr

Drug firm Novartis India Friday said its parent Novartis AG has offloaded 1.42 percent stake in it through open market for a consideration of over Rs 25 crore to meet market regulator SEBI guidelines.

Novartis appoints Citigroup as broker for Indian co share sale

Drug major Novartis India Thursday said its Swiss promoter Novartis AG has appointed Citigroup Capital Markets as the broker for the proposed share sale to reduce stake in the Indian entity.

SC decision on Novartis to benefit poor patients: Pharma cos

Novartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options".

Supreme Court rejects Novartis cancer drug Glivec patent plea

Glivec, used in treating chronic myeloid leukemia and some other cancers, costs a patient about Rs 1.2 lakh/month, much higher than Rs 8,000 which is the price of the generic drug.

Novartis shares up 4% after Swiss-promoter says to cut stake

Shares of Novartis India on Wednesday closed higher by 3.75 percent, adding Rs 68 crore to its market capitalisation, after its Swiss-promoter said it intends to reduce stake in the Indian entity.

Novartis AG to reduce promoters stake in Novartis India

Novartis India on Thursday said it's Swiss-promoter Novartis AG intends to reduce its stake in the Indian entity to enable it to meet Sebi guidelines on the minimum public shareholding in the listed companies.

Novartis tells SC it has right to patent its cancer drug

The Supreme Court today asked Swiss pharma giant Novartis AG whether it should not sell its anti-cancer drug for Rs 5 each to benefit common man.

Novartis tells SC it has right to patent its cancer drug

The Supreme Court today asked Swiss pharma giant Novartis AG whether it should not sell its anti-cancer drug for Rs 5 each to benefit common man.